Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.82 -1.3%	$0.76	$0.45 ▼ $1.99	$62.63M	1.53	260,666 shs	78,742 shs
MTVA MetaVia	$0.65 +1.3%	$0.67	$0.56 ▼ $4.32	$15.68M	0.26	325,466 shs	75,262 shs
OVID Ovid Therapeutics	$0.90 -7.1%	$0.45	$0.24 ▼ $1.47	$64.14M	0.2	972,557 shs	1.64 million shs
VRCA Verrica Pharmaceuticals	$6.18 +3.7%	$6.66	$3.82 ▼ $30.90	$58.07M	1.92	42,994 shs	29,882 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	0.00%	-0.60%	-8.22%	+16.77%	+21.65%
MTVA MetaVia	0.00%	+1.60%	-5.03%	-8.44%	+63,999,900.00%
OVID Ovid Therapeutics	0.00%	+88.39%	+76.36%	+222.15%	-14.16%
VRCA Verrica Pharmaceuticals	0.00%	-6.14%	-26.99%	-7.42%	-78.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	4.5026 of 5 stars	3.5	5.0	4.7	2.9	0.8	0.6
MTVA MetaVia	2.4734 of 5 stars	3.5	0.0	0.0	3.1	0.0	1.3
OVID Ovid Therapeutics	4.4083 of 5 stars	3.6	3.0	4.6	2.4	2.5	0.6
VRCA Verrica Pharmaceuticals	4.5226 of 5 stars	3.1	5.0	4.7	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	3.00	Buy	$4.00	390.80% Upside
MTVA MetaVia	3.00	Buy	$7.50	1,057.41% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	244.06% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,194.50% Upside

Current Analyst Ratings Breakdown

Latest MTVA, CUE, OVID, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	6.74	N/A	N/A	$0.28 per share	2.91
MTVA MetaVia	N/A	N/A	N/A	N/A	$0.92 per share	N/A
OVID Ovid Therapeutics	$570K	112.40	N/A	N/A	$0.96 per share	0.94
VRCA Verrica Pharmaceuticals	$7.57M	7.71	N/A	N/A	($1.07) per share	-5.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	N/A
MTVA MetaVia	-$27.59M	N/A	0.00	N/A	N/A	N/A	-212.00%	-107.21%	11/6/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	N/A
VRCA Verrica Pharmaceuticals	-$76.58M	-$8.28	N/A	N/A	N/A	N/A	N/A	-115.48%	11/3/2025 (Estimated)

Latest MTVA, CUE, OVID, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.70	$0.02	+$0.72	$0.02	$4.37 million	$12.70 million
8/7/2025	Q2 2025	MTVA MetaVia	-$0.32	-$0.26	+$0.06	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	0.01	1.60	1.60
MTVA MetaVia	N/A	2.08	2.08
OVID Ovid Therapeutics	0.23	4.72	4.72
VRCA Verrica Pharmaceuticals	N/A	1.26	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
MTVA MetaVia	1.37%
OVID Ovid Therapeutics	72.24%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	12.26%
MTVA MetaVia	0.80%
OVID Ovid Therapeutics	13.10%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	76.85 million	67.43 million	Optionable
MTVA MetaVia	8	24.20 million	24.00 million	N/A
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
VRCA Verrica Pharmaceuticals	40	9.45 million	4.35 million	Optionable

MTVA, CUE, OVID, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

August 14, 2025 | marketbeat.com

Verrica Posts Profit in Fiscal Q2

August 14, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Verrica Pharmaceuticals Regains Nasdaq Compliance

August 12, 2025 | msn.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

August 12, 2025 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Gap Down - What's Next?

July 26, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed ...

July 11, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MTVA, CUE, OVID, and VRCA Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.82 -0.01 (-1.33%)

As of 03:13 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

MetaVia NASDAQ:MTVA

$0.65 +0.01 (+1.25%)

As of 02:26 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Ovid Therapeutics NASDAQ:OVID

$0.90 -0.07 (-7.11%)

As of 03:21 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Verrica Pharmaceuticals NASDAQ:VRCA

$6.18 +0.22 (+3.69%)

As of 03:21 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time